Test

Clinical Application

Methodology

ALL Panel

Detection of BCR-ABL, E2A-PBX1, MLL-AF4 and TEL-AML1

Real-Time Quantitative PCR

E2A-PBX1 t(1;19)

Minimal residual disease (MRD) detection of t (1; 19) for ALL.

Real-Time Quantitative PCR

MLL-AF4 t(4;11)

MRD detection of t (4; 11) and prognostic indicator for ALL.

Real-Time Quantitative PCR

TEL-AML1 t(12;21)

MRD detection of t (12; 21) and prognostic indicator for ALL.

Real-Time Quantitative PCR

BCR-ABL t(9;22)

Detection and quantitative monitoring of t (9; 22) for CML and ALL.

Real-Time Quantitative PCR

AML Panel

Detection of PML-RARA, AML1-ETO and CBFB-MYH11

Real-Time Quantitative PCR

PML-RARA t(15;17)

Detection and quantitative monitoring of t (15; 17) for APL. STAT same day analysis available for diagnostic specimens.

Real-Time Quantitative PCR

AML 1-ETO t(8;21)

Detection and monitoring of t (8; 21). Favorable prognosis in AML.

Real-Time Quantitative PCR

CBFB-MYH11 inv(16)

Detection and monitoring of inv (16). Favorable prognosis in AML.

Real-Time Quantitative PCR

FIPILI-PDGFRA del(4q12)

Detection and monitoring of del (4q12) in HES (hypereosinophilic syndrome) and CEL (chronic eosinophilic leukemia).

Real-Time Quantitative PCR

JAK2+

V617F JAK2 (Janus kinas 2) point mutation detection for diagnosis of myeloproliferative disorders. High detection sensitivity (0.1 %). Heterozygous versus Homozygous profile detection.

Point Mutation Assay

KRAS

Certain mutations in the KRAS gene prevent the therapeutic success of therapies that can cause this kind of activation that renders anti-EGFR therapies ineffective.

Point Mutation Assay

BRAF

BRAF encodes a serine/threonine protein kinase which plays a role in signaling pathways involved in cell proliferation and differentiation.Some BRAF mutations significantly increase the BRAF gene product leading to neoplastic growth. Identification of BRAF genetic variants is thus the key to the best therapy for melanoma and thyroid cancer.

Point Mutation Assay

Hemochromatosis

 

Target Mutation assay

FMF

 

Full Sequencing

PGX-5FU

5-Fluorouracil (5-FU) is widely and successfully used for the treatment of solid tumors. In some patients, however, an enzyme variant results in the need of therapy adjustment. The PGX-5FU test identifies the most common mutation with therapeutic relevance for 5-FU treatment.

 

Alpha 1-antitripsine

 

Target Mutation assay

(PI*S,PI*Z)

 
مركز تحقيقات هماتولوژی
دانشگاه علوم پزشكی شيراز
نشانی: شیراز - بلوارکریم خان زند - میدان نمازی - بیمارستان نمازی - مرکز تحقیقات هماتولوژی
تلفن های تماس: 6125617-0711
فاکس: 6473239-0711
پست الکترونیک:
hematology@sums.ac.ir


کارگاه ها و همایش ها
شرکت در کنگره ها
 کنگره هاي برگزار شده توسط مركز

آئین نامه ها و فرم هاتازه های سایت